Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Opening the black box: explainable AI for automated bioturbation analysis in cores and outcrops.

Scientific reports·2026
Same author

Feasibility of collecting longitudinal patient-reported outcomes in individuals with relapsed or refractory large B-cell lymphoma who received chimeric antigen receptor T-cell (CART) therapy.

BMC cancer·2024
Same author

Current endodontic practice and use of newer technologies in Australia and New Zealand.

Australian dental journal·2023
Same author

Hopes and fears regarding care robots: Content analysis of newspapers in East Asia and Western Europe, 2001-2020.

Frontiers in rehabilitation sciences·2022
Same author

Dentists' preferences in implant maintenance and hygiene instruction.

Australian dental journal·2021
Same author

Reimbursement recommendations for cancer drugs supported by phase II evidence in Canada.

Current oncology (Toronto, Ont.)·2020

Related Experiment Video

Updated: Jun 19, 2026

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

I-Tositumomab in lymphoma.

M C Cheung1, J A Maceachern, A E Haynes

  • 1Cancer Care Ontario, Program in Evidence-Based Care, McMaster University, Hamilton, ON.

Current Oncology (Toronto, Ont.)
|October 29, 2009
PubMed
Summary

Radioimmunoconjugates like iodine-131 tositumomab show promise for relapsed non-Hodgkin lymphoma (NHL). While effective in some patients, further research is needed to clarify long-term benefits and manage toxicities.

Keywords:
131I–TositumomabBexxarindolent lymphomasystematic review

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Related Experiment Videos

Last Updated: Jun 19, 2026

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Immunotherapy

Background:

  • Radioimmunoconjugates, specifically radioisotope-bound monoclonal antibodies, offer targeted radiation delivery to lymphoma sites.
  • Initial studies of iodine-131 tositumomab (131I-tositumomab) in non-Hodgkin lymphoma (NHL) indicate potential benefits for relapsed or refractory indolent disease.
  • Widespread adoption is limited by concerns regarding toxicity and uncertain long-term efficacy.

Purpose of the Study:

  • To systematically review and evaluate the evidence on the benefits and risks of 131I-tositumomab in lymphoma treatment.
  • To identify predictors of response and toxicity associated with 131I-tositumomab therapy.
  • To assess the role of pre-treatment dosimetry and imaging in guiding 131I-tositumomab use.

Main Methods:

  • A comprehensive literature search was conducted to identify relevant trials.
  • Eighteen trials investigating 131I-tositumomab in adult patients with NHL were included in the review.
  • Data on response rates, time to progression, survival, toxicity, and predictive factors were analyzed.

Main Results:

  • Overall response rates for 131I-tositumomab in relapsed/refractory indolent NHL ranged from 67% to 83%.
  • In follicular NHL patients refractory to rituximab, response rates were 65%-72%.
  • Clear improvements in time to progression or survival were not established in rituximab-naïve patients with relapsed/refractory indolent or transformed NHL.

Conclusions:

  • 131I-tositumomab demonstrates activity in relapsed and refractory non-Hodgkin lymphoma.
  • The agent should be considered for selected patients with relapsed or refractory NHL.
  • Further investigation is warranted to optimize patient selection and manage potential toxicities for long-term benefit.